Drug Approval | July 03, 2022
Pfizer submits new drug application to the U.S. FDA for Paxlovid
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Govt committed to supporting pharma companies with industry-friendly policies
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Bringing next-gen cannabinoid therapeutics to cancer patients
Subscribe To Our Newsletter & Stay Updated
